In individuals with low blood eosinophil levels, this medication, which targets the IL-33 pathway, resulted in a marginally better reduction in exacerbation; this suggests that the IL-33 pathway may be more significant in type 2 low severe asthma. This evidence concerns the gene IL33 and asthma.